MA39443A1 - Nouvelle formulation de méloxicam - Google Patents

Nouvelle formulation de méloxicam

Info

Publication number
MA39443A1
MA39443A1 MA39443A MA39443A MA39443A1 MA 39443 A1 MA39443 A1 MA 39443A1 MA 39443 A MA39443 A MA 39443A MA 39443 A MA39443 A MA 39443A MA 39443 A1 MA39443 A1 MA 39443A1
Authority
MA
Morocco
Prior art keywords
meloxicam
pain
new
meloxicam formulation
effectively relieve
Prior art date
Application number
MA39443A
Other languages
English (en)
Inventor
H William Bosch
Original Assignee
Iceutica Pty Ltd
H William Bosch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54768708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39443(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iceutica Pty Ltd, H William Bosch filed Critical Iceutica Pty Ltd
Publication of MA39443A1 publication Critical patent/MA39443A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formes posologiques unitaires de méloxicam contenant 5 mg ou 10 mg de méloxicam qui soulagent efficacement la douleur et ont les propriétés pharmacocinétiques souhaitables. Les formes posologiques unitaires soulagent efficacement la douleur lorsqu'une dose unitaire est administrée à un patient et sont utiles pour traiter une douleur telle que la douleur due à l'arthrose, l'exposition systémique au méloxicam demeurant relativement basse.
MA39443A 2014-06-09 2015-06-09 Nouvelle formulation de méloxicam MA39443A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009860P 2014-06-09 2014-06-09
US14/675,410 US9526734B2 (en) 2014-06-09 2015-03-31 Formulation of meloxicam
PCT/US2015/034923 WO2015191595A1 (fr) 2014-06-09 2015-06-09 Nouvelle formulation de méloxicam

Publications (1)

Publication Number Publication Date
MA39443A1 true MA39443A1 (fr) 2017-10-31

Family

ID=54768708

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39443A MA39443A1 (fr) 2014-06-09 2015-06-09 Nouvelle formulation de méloxicam

Country Status (18)

Country Link
US (7) US9526734B2 (fr)
EP (1) EP3151835A4 (fr)
JP (1) JP2017517551A (fr)
KR (1) KR20170017915A (fr)
CN (1) CN107073010A (fr)
AP (1) AP2016009611A0 (fr)
AU (1) AU2015274838B2 (fr)
BR (1) BR112016027435A2 (fr)
CA (1) CA2951383A1 (fr)
EA (1) EA201692392A1 (fr)
IL (1) IL248699A0 (fr)
MA (1) MA39443A1 (fr)
MX (1) MX2016016212A (fr)
NZ (1) NZ726610A (fr)
PH (1) PH12016502336A1 (fr)
SG (1) SG11201610179QA (fr)
WO (1) WO2015191595A1 (fr)
ZA (1) ZA201700022B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN108949699B (zh) 2018-08-03 2020-09-04 江南大学 一种分泌美洛昔康单克隆抗体的杂交瘤细胞株及其应用
CN111346097B (zh) * 2018-12-22 2023-03-24 江苏先声药业有限公司 一种组合物及其制备方法
EP3958841A1 (fr) * 2019-04-22 2022-03-02 Mylan Specialty L.P. Compositions de co-cristaux de méloxicam
JP7348703B2 (ja) * 2019-06-28 2023-09-21 エスエス製薬株式会社 メロキシカム含有造粒物
US20210093642A1 (en) * 2019-09-26 2021-04-01 Cadila Healthcare Limited STABLE AQUEOUS PARENTERAL SOLUTIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
WO2021224815A1 (fr) * 2020-05-06 2021-11-11 Cadila Healthcare Limited Solutions parentérales aqueuses stables de médicament anti-inflammatoire non stéroïdien (ains)
CN115844820B (zh) * 2022-11-23 2023-08-29 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172546A (en) 1961-05-19 1965-03-09 Union Carbide Corp Size reduction of biological substances
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
IT1082518B (it) 1977-01-25 1985-05-21 Fiat Spa Specchio a cristallo liquido da impiegare particolarmente come retrovisore per veicoli
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
BR9500758A (pt) 1994-03-02 1995-10-24 Lilly Co Eli Formulaçoes farmacêuticas para administraçao oral
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
WO1998035666A1 (fr) 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
JP2001513563A (ja) 1997-08-27 2001-09-04 ヘキサル アーゲー 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1066825A1 (fr) 1999-06-17 2001-01-10 The Procter & Gamble Company Produit antimicrobien pour les soins du corps
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1913939B1 (fr) 2000-06-27 2017-05-31 Vectura Limited Formulations destinées à être utilisées dans des dispositifs d'inhalation
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
ATE419834T1 (de) 2000-11-20 2009-01-15 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
DK2283817T3 (en) 2000-11-30 2016-09-05 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
AU2002232492A1 (en) 2000-12-06 2002-06-18 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
DE60203506T2 (de) 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
DK1443912T3 (da) 2001-10-12 2008-01-21 Elan Pharma Int Ltd Sammensætninger med en kombination af umiddelbare og kontrollerede frisætningsegenskaber
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US6825161B2 (en) 2002-04-26 2004-11-30 Salvona Llc Multi component controlled delivery system for soap bars
WO2004019937A1 (fr) 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Composition pharmaceutique de metaxalone a biodisponibilite orale amelioree
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
CA2499819A1 (fr) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Nouveaux sels d'addition acides de raloxifene et/ou solvates de ceux-ci, procede ameliore permettant la purification de ces sels d'addition acides et/ou de ces solvates, et compositions pharmaceutiques les contenant
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
WO2004058216A2 (fr) 2002-12-17 2004-07-15 Elan Pharma International Ltd. Broyage de quantites de composes candidats nanoparticulaires de l'ordre du microgramme
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004066981A1 (fr) 2003-01-29 2004-08-12 Sun Pharmaceutical Industries Limited Composition pharmaceutique orale a liberation controlee contenant du metaxalone en tant qu'agent actif
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
EP1620075B1 (fr) 2003-05-07 2020-06-24 Samyang Biopharmaceuticals Corporation Granules a teneur elevee en plastique, destines a la fabrication de comprimes a dissolution rapide
PT1638527E (pt) 2003-06-27 2007-02-28 Bioprogress Spa Produto compósito obtido por co-trituração de um princípio activo com um copolímero de n-vinil-2-pirrolidona/acetato de vinilo
JP2009513512A (ja) 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
EP1651189B1 (fr) 2003-08-08 2008-12-03 Elan Pharma International Limited Nouvelles compositions de metaxalone
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
WO2005020933A2 (fr) 2003-09-02 2005-03-10 University Of South Florida Nanoparticules pour apport de medicament
JP2007507339A (ja) 2003-10-01 2007-03-29 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 粒子製造装置及び方法
ES2366646T3 (es) 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
WO2005087204A1 (fr) 2004-03-08 2005-09-22 Spiridon Spireas Compositions biodisponibles de metaxalone et procedes de production correspondant
EP1768647B1 (fr) 2004-06-17 2012-08-08 Virun, Inc. Compositions comprenant une protéine adhérant aux muqueuses et principe actif pour la délivrance d'agents dans des muqueuses
WO2006009419A1 (fr) 2004-07-19 2006-01-26 Luis Cordova Boone Pneus a double bande de roulement
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (fr) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Forme posologique pharmaceutique comprenant meloxicam
CA2598204C (fr) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Composition de petites particules medicamenteuses chauffee et stabilisee
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CN101094659A (zh) 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
ES2340518T3 (es) 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
JP2009510007A (ja) * 2005-09-30 2009-03-12 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む医薬調製
US20080292584A1 (en) 2005-10-14 2008-11-27 Mutual Pharmaceutical Company, Inc. Metaxalone products, method of manufacture, and method of use
WO2007070851A2 (fr) 2005-12-15 2007-06-21 Acusphere, Inc. Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
WO2007070852A2 (fr) 2005-12-15 2007-06-21 Acusphere, Inc. Procédés de préparation de formulations pharmaceutiques à base de particules destinées à une administration parentérale
EP1978933A2 (fr) 2005-12-15 2008-10-15 Acusphere, Inc. Procédés de préparation de formulations pharmaceutiques à base de particules destinées à une administration orale
WO2007074477A2 (fr) 2005-12-29 2007-07-05 Dabur Pharma Limited Polymorphes de métaxalone
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101484169A (zh) 2006-06-23 2009-07-15 依兰药物国际有限公司 包含纳米颗粒美洛昔康和控释氢可酮的组合物
CN104288103B (zh) 2006-06-30 2019-10-15 伊休蒂卡有限公司 用于制备纳米粒形式的生物活性化合物的方法
IN2014MN00380A (fr) 2006-06-30 2015-06-19 Iceutica Pty Ltd
CN100386312C (zh) 2006-07-18 2008-05-07 上海世景国际贸易有限公司 2，4-二氨基苯磺酸及其盐的合成方法
WO2008013416A1 (fr) 2006-07-27 2008-01-31 Amorepacific Corporation Procédé pour la préparation d'une poudre comprenant des nanoparticules de médicament peu soluble
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
RU2010153904A (ru) 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
AP2015008965A0 (en) 2009-04-24 2016-01-31 Iceutica Pty Ltd Method for improving the dissolutionprofile of a biologically active material
MX359793B (es) 2009-04-24 2018-10-08 Iceutica Pty Ltd Producción de nanopartículas encapsuladas a escala comercial.
CA2759125C (fr) 2009-04-24 2017-08-15 Iceutica Pty Ltd Nouvelle formulation d'indomethacine
MX2011011219A (es) 2009-04-24 2012-02-08 Iceutica Pty Ltd Una formulacion novedosa de meloxicam.
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
US20120263760A1 (en) 2009-04-24 2012-10-18 Aaron Dodd Novel formulation of metaxalone
CA2759122A1 (fr) 2009-04-24 2010-10-28 Iceutica Pty Ltd Nouvelle formulation de naproxene
MY159098A (en) 2009-04-24 2016-12-15 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
MX347290B (es) 2009-04-24 2017-04-17 Iceutica Pty Ltd Una formulacion novedosa de diclofenaco.
US8545879B2 (en) * 2009-08-31 2013-10-01 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam
RU2684914C2 (ru) 2013-07-22 2019-04-16 Айсьютика Инк. Препараты метаксалона
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam

Also Published As

Publication number Publication date
US9526734B2 (en) 2016-12-27
US20170246178A1 (en) 2017-08-31
US20210213028A1 (en) 2021-07-15
WO2015191595A1 (fr) 2015-12-17
US9649318B2 (en) 2017-05-16
AP2016009611A0 (en) 2016-12-31
CN107073010A (zh) 2017-08-18
BR112016027435A2 (pt) 2017-10-17
US20200085835A1 (en) 2020-03-19
EP3151835A4 (fr) 2018-01-10
US20150352122A1 (en) 2015-12-10
PH12016502336A1 (en) 2017-02-13
EP3151835A1 (fr) 2017-04-12
MX2016016212A (es) 2017-02-23
US20160101110A1 (en) 2016-04-14
IL248699A0 (en) 2017-01-31
KR20170017915A (ko) 2017-02-15
EA201692392A1 (ru) 2017-03-31
US20230414630A1 (en) 2023-12-28
US20180050042A1 (en) 2018-02-22
US9808468B2 (en) 2017-11-07
SG11201610179QA (en) 2017-01-27
JP2017517551A (ja) 2017-06-29
NZ726610A (en) 2020-05-29
AU2015274838B2 (en) 2019-07-04
AU2015274838A1 (en) 2016-12-08
ZA201700022B (en) 2018-05-24
CA2951383A1 (fr) 2015-12-17

Similar Documents

Publication Publication Date Title
MA39443A1 (fr) Nouvelle formulation de méloxicam
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MX2018001584A (es) Composiciones de solución sólida para aines.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA38358A1 (fr) Formulations de composés organiques
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
CO7310521A2 (es) Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
AR100153A1 (es) Medicamento
MA42361A1 (fr) Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one
EA201692532A1 (ru) Антимикробные композиции с шипучими веществами
EA202190033A1 (ru) Соединения пиразола и имидазола для ингибирования il-17 и ror-гамма